Opus Genetics (IRD) EBIT (2010 - 2026)
Opus Genetics (IRD) reported EBIT of -$14.4 million for Q1 2026, down 44.67% year-over-year from -$26.0 million in Q1 2025, and down 25.42% quarter-over-quarter from -$11.5 million in Q4 2025.
Opus Genetics (IRD) EBIT (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has 17 years of EBIT data on file, last reported at -$14.4 million in Q1 2026.
- EBIT for Q1 2026 came in at -$14.4 million, down 44.67% year-over-year; the trailing twelve-month figure through Mar 2026 was -$43.0 million (up 33.07% YoY), and the FY2025 annual result was -$38.6 million, up 37.82% from the prior year.
- EBIT declined to -$14.4 million in Q1 2026 per IRD's latest filing, from -$11.5 million in the prior quarter.
- Over five years, EBIT peaked at $34.2 million in Q4 2022 and troughed at -$38.0 million in Q4 2024.
- A 5-year average of -$6.3 million and a median of -$7.7 million in 2024 frame the typical range for EBIT.
- The sharpest annual moves came in 2022 and 2024: EBIT soared 656.26% in 2022, then sank 600.48% in 2024.
- A 5-year view of EBIT shows it stood at $34.2 million in 2022, then plunged by 115.87% to -$5.4 million in 2023, then slumped by 600.48% to -$38.0 million in 2024, then soared by 69.88% to -$11.5 million in 2025, then fell by 25.42% to -$14.4 million in 2026.
- Business Quant data shows IRD's EBIT at -$14.4 million in Q1 2026, -$11.5 million in Q4 2025, and -$8.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.76 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.51 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Opus Genetics | 355.39 Mn | 295.43 Mn | - | -14.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.36 Mn |
| Dec 31, 2025 | -11.45 Mn |
| Sep 30, 2025 | -8.31 Mn |
| Jun 30, 2025 | -8.91 Mn |
| Mar 31, 2025 | -9.93 Mn |
| Dec 31, 2024 | -38.03 Mn |
| Sep 30, 2024 | -8.01 Mn |
| Jun 30, 2024 | -8.33 Mn |
| Mar 31, 2024 | -7.71 Mn |
| Dec 31, 2023 | -5.43 Mn |
| Sep 30, 2023 | 6.39 Mn |
| Jun 30, 2023 | -5.39 Mn |
| Mar 31, 2023 | -6.13 Mn |
| Dec 31, 2022 | 34.21 Mn |
| Sep 30, 2022 | -4.54 Mn |
| Jun 30, 2022 | -4.94 Mn |
| Mar 31, 2022 | -6.51 Mn |
| Dec 31, 2021 | -6.15 Mn |
| Sep 30, 2021 | -4.23 Mn |
| Jun 30, 2021 | -7.14 Mn |